A New Treatment Approach

A randomized controlled trial published in Psychological Medicine has demonstrated that a digital therapy called attexis produces significant and clinically relevant reductions in ADHD symptoms in adults. The study represents one of the most rigorous evaluations yet of a digital therapeutic for attention deficit hyperactivity disorder and could open a new treatment pathway for the millions of adults who live with the condition.

ADHD affects an estimated 4 to 5 percent of adults worldwide, many of whom were not diagnosed until adulthood. While stimulant medications like Adderall and Ritalin remain the most common treatment, they are not effective for all patients and carry side effects and risks that make some individuals unable or unwilling to take them. Non-pharmacological interventions like cognitive behavioral therapy have shown promise but face barriers of cost, availability, and the time commitment required for regular sessions.

How Attexis Works

Attexis is a software-based therapeutic intervention delivered through a smartphone or tablet application. Unlike general-purpose mindfulness or productivity apps, attexis is designed as a regulated medical device that targets specific cognitive processes implicated in ADHD.

The therapy works by presenting users with structured cognitive training exercises designed to improve attention regulation, impulse control, and executive function. The exercises are adaptive, automatically adjusting their difficulty based on the user's performance to maintain an optimal level of challenge. Sessions are typically short, designed to be completed in 15 to 20 minutes, and are meant to be used regularly over a period of weeks.

Key features of the digital therapy include:

  • Structured cognitive training exercises targeting attention and executive function
  • Adaptive difficulty that responds to individual performance
  • Short daily sessions designed to fit into busy schedules
  • Progress tracking and reporting for both patients and clinicians
  • Evidence-based design informed by neuroscientific understanding of ADHD

Trial Design and Results

The randomized controlled trial compared adults using attexis against a control group over a multi-week treatment period. Participants were assessed using validated clinical instruments that measure ADHD symptom severity, including measures of inattention, hyperactivity, and impulsivity.

The results showed that participants using attexis experienced statistically significant and clinically meaningful reductions in overall ADHD symptom severity compared to the control group. The improvements were observed across multiple symptom domains, suggesting that the therapy addresses the broad constellation of difficulties that characterize ADHD rather than targeting just one aspect of the condition.

The clinical significance of the findings is particularly noteworthy. While many studies of ADHD interventions find statistically significant effects, fewer demonstrate improvements that are large enough to be considered clinically meaningful, that is, noticeable to patients in their daily lives. The attexis trial met this higher bar, suggesting that the therapy produces real-world benefits for users.

Implications for ADHD Treatment

The trial results add to a growing body of evidence supporting digital therapeutics as a legitimate treatment modality for neuropsychiatric conditions. The FDA has already approved digital therapeutics for conditions including substance use disorders and insomnia, and ADHD represents a natural extension of this approach given the cognitive nature of the condition.

For adults with ADHD, a validated digital therapy could offer several advantages over existing treatments. It can be accessed from anywhere with a smartphone, eliminating the geographic barriers that limit access to specialized clinicians. It avoids the side effects associated with stimulant medications. And it can be used in combination with other treatments, potentially enhancing the overall effectiveness of a comprehensive treatment plan.

The therapy is particularly relevant for the large number of adults who have recently received ADHD diagnoses but face long wait times for specialist appointments and therapy sessions. A digital therapeutic could begin providing benefits immediately while patients wait for other services to become available.

The Digital Therapeutics Landscape

Attexis enters a rapidly evolving digital therapeutics market that has attracted significant investment and attention in recent years. Several companies are developing digital treatments for ADHD and related conditions, and regulatory agencies in the United States and Europe are developing frameworks for evaluating and approving these products.

The market has faced challenges, however. Some early digital therapeutics companies have struggled commercially despite clinical evidence supporting their products, in part because insurance coverage and physician adoption have been slower than anticipated. The attexis trial results could help build the case for broader insurance coverage of digital ADHD treatments by demonstrating the kind of rigorous clinical evidence that payers increasingly demand.

What Comes Next

The researchers note that while the trial results are encouraging, further studies are needed to determine the long-term durability of treatment effects, the optimal duration and frequency of use, and how the therapy performs in combination with medications and other interventions. Larger trials with more diverse patient populations will also be important for establishing the generalizability of the findings. Nevertheless, the current results represent a meaningful step forward in the development of accessible, evidence-based treatments for adult ADHD, a condition that remains undertreated despite its significant impact on quality of life, productivity, and mental health.

This article is based on reporting by Medical Xpress. Read the original article.